NASDAQ : ALT
Altimmune, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 396.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 396.82M |
| Enterprise Value | 106.56M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 194.52M |
| Shares Outstanding | 194.52M |
| Shares Change (YoY) | +68.90% |
| Shares Change (QoQ) | +49.00% |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 62.77% |
| Float | 164.34M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12,800.52 |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3,437.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 26.78 |
| Quick Ratio | 26.37 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.92 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -28.87% |
| Return on Assets (ROA) | -17.20% |
| Return on Invested Capital (ROIC) | -17.95% |
| Return on Capital Employed (ROCE) | -19.18% |
| Weighted Average Cost of Capital (WACC) | 4.84% |
| Revenue Per Employee | $544 |
| Profits Per Employee | -$1.61M |
| Employee Count | 57 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.06 |
| 52-Week Price Change | -49.00% |
| 50-Day Moving Average | 2.83 |
| 200-Day Moving Average | 3.28 |
| Relative Strength Index (RSI) | 26.67 |
| Average Volume (20 Days) | 3,765,333 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 42.23M |
| Short Previous Month | 46.08M |
| Short % of Shares Out | 21.71% |
| Short % of Float | 25.70% |
| Short Ratio (days to cover) | 10.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 31,000 |
| Gross Profit | -66.69M |
| Operating Income | -98.73M |
| Pretax Income | -91.76M |
| Net Income | -91.76M |
| EBITDA | -98.63M |
| EBIT | -98.73M |
| Loss Per Share | -$0.73 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 326.28M |
| Total Debt | 36.02M |
| Net Cash | 290.26M |
| Net Cash Per Share | $1.49 |
| Equity (Book Value) | 474.21M |
| Book Value Per Share | 2.44 |
| Working Capital | 322.31M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -76.51M |
| Capital Expenditures | -54,000 |
| Depreciation & Amortization | 99,000 |
| Net Borrowing | 20.40M |
| Free Cash Flow | -76.56M |
| FCF Per Share | -$0.39 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -318,493.55% |
| Pretax Margin | -296,000.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -68.90% |
| Shareholder Yield | -68.90% |
| Earnings Yield | -35.59% |
| FCF Yield | -19.29% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.11 |
| Price Target Difference | 738.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 296.85% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |